Eli Lilly Adds Warning Labels To Zyprexa

By Jacqueline Bell

Law360, New York (October 09, 2007, 12:00 AM ET) -- Drug maker Eli Lilly and Co. has decided to put stronger product labels on its blockbuster antipsychotic treatment Zyprexa, adding new warnings about the potential for weight gain and elevated blood sugar or cholesterol levels.

Zyprexa, the brand name version of olanzapine, is an atypical anti-psychotic prescription medication used to treat symptoms of various psychiatric conditions, including schizophrenia and bipolar disorder.

Lilly said the decision reflected both new analysis of clinical trial data and ongoing discussions with the U.S. Food and Drug Administration. The company also...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles